Effect of intrasphincteric botulinum toxin on postoperative urinary retention following stapled hemorrhoidopexy: a randomized, double-blind, placebo-controlled trial

Postoperative urinary retention (POUR) is a frequent and clinically significant complication following stapled hemorrhoidopexy, often resulting in catheterization, prolonged hospitalization, and patient discomfort. Strategies to reduce POUR remain limited. Intrasphincteric botulinum toxin (BTX) injection may decrease internal anal sphincter tone and indirectly reduce urinary dysfunction. To evaluate the effect of intrasphincteric BTX type A injection on the incidence of POUR following stapled hemorrhoidopexy in a secondary analysis of a prospective randomized controlled trial originally designed to assess postoperative pain outcomes. In this double-blind, placebo-controlled trial, 68 adult patients with grade III-IV hemorrhoids undergoing stapled hemorrhoidopexy at two tertiary hospitals were randomized (1:1) to receive either 50 units of BTX A or placebo injected into the internal anal sphincter intraoperatively. The primary outcome was POUR, defined as failure to void within six hours postoperatively with a bladder volume > 400 mL on ultrasound requiring catheterization. Secondary outcomes included postoperative pain, gas incontinence, bleeding, and anal stenosis. POUR occurred in 30 patients (44.1%). The incidence was significantly lower in the BTX group compared with placebo (20.6% vs. 67.6%, P < 0.001). In multivariable logistic regression adjusted for age and sex, placebo treatment was independently associated with higher odds of POUR (adjusted OR 8.87, 95% CI 2.82-27.95; P < 0.001). No significant differences were observed in postoperative bleeding or gas incontinence. Intrasphincteric BTX injection significantly reduces postoperative urinary retention following stapled hemorrhoidopexy and may represent an effective perioperative strategy to improve surgical.Registration: IRCT20130826014483N12; Registered 25 June 2025 (Retrospectively registered).

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-05-16
DOI
https://doi.org/10.1038/s41598-026-53489-1
Primary Topic
Anorectal Disease Treatments and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of intrasphincteric botulinum toxin on postoperative urinary retention following stapled hemorrhoidopexy: a randomized, double-blind, placebo-controlled trial

Mina Alvandipour, Maryam Vahidpoor, Ava Ranjbar, Sina Safari et al.
Scientific Reports
Anorectal Disease Treatments and Outcomes
article

Effect of intrasphincteric botulinum toxin on postoperative urinary retention following stapled hemorrhoidopexy: a randomized, double-blind, placebo-controlled trial

Mina Alvandipour, Maryam Vahidpoor, Ava Ranjbar, Sina Safari, Mehdi Karimi
article en

Abstract

Postoperative urinary retention (POUR) is a frequent and clinically significant complication following stapled hemorrhoidopexy, often resulting in catheterization, prolonged hospitalization, and patient discomfort. Strategies to reduce POUR remain limited. Intrasphincteric botulinum toxin (BTX) injection may decrease internal anal sphincter tone and indirectly reduce urinary dysfunction. To evaluate the effect of intrasphincteric BTX type A injection on the incidence of POUR following stapled hemorrhoidopexy in a secondary analysis of a prospective randomized controlled trial originally designed to assess postoperative pain outcomes. In this double-blind, placebo-controlled trial, 68 adult patients with grade III-IV hemorrhoids undergoing stapled hemorrhoidopexy at two tertiary hospitals were randomized (1:1) to receive either 50 units of BTX A or placebo injected into the internal anal sphincter intraoperatively. The primary outcome was POUR, defined as failure to void within six hours postoperatively with a bladder volume > 400 mL on ultrasound requiring catheterization. Secondary outcomes included postoperative pain, gas incontinence, bleeding, and anal stenosis. POUR occurred in 30 patients (44.1%). The incidence was significantly lower in the BTX group compared with placebo (20.6% vs. 67.6%, P < 0.001). In multivariable logistic regression adjusted for age and sex, placebo treatment was independently associated with higher odds of POUR (adjusted OR 8.87, 95% CI 2.82-27.95; P < 0.001). No significant differences were observed in postoperative bleeding or gas incontinence. Intrasphincteric BTX injection significantly reduces postoperative urinary retention following stapled hemorrhoidopexy and may represent an effective perioperative strategy to improve surgical.Registration: IRCT20130826014483N12; Registered 25 June 2025 (Retrospectively registered).

Scientific Reports
Babol University of Medical Sciences (IR), Mazandaran University of Medical Sciences (IR)
Good health and well-being
Openalex Percentile: Top 4%
Anorectal Disease Treatments and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.